Alzheimer’s Disease

Alzheimer’s disease currently affects nearly 6 million Americans. It is estimated that by the year 2050, this disease could affect 160 million people worldwide. Until now, this disease was uniformly fatal. There was no cure. The few approved drugs only slowed the decline for a brief time.

“Everyone knows someone who is a cancer survivor; no one knows an Alzheimer’s survivor….until now.” Dr Dale Bredesen.

Since 2014, this statement is no longer true. In that year, Dr. Bredesen, of the UCLA Buck Institute for Aging Research, published his landmark paper describing the reversal of the dementia symptoms in patients with Alzheimer’s Disease.1 That initial study on 10 patients has now expanded to hundreds.

The first patient is nearly 6 years into treatment and continues with normal cognition. The results have been replicated in hundreds of patients since.

His treatment protocol is named ReCODE (Reversal of Cognitive Decline). Dr. Bredesen followed up his scientific publications with a New York Times best-selling book, The End of Alzheimer’s.

Dr. Bredesen began to train other physicians in the ReCODE protocol. Dr. Koziarski was one of the physicians included in the early training program.

ReCODE

Not surprisingly, the ReCODE protocol is like an ultra-refined functional medicine evaluation and treatment. The beauty is, that Dr. Bredesen’s arduous work in the lab for the 30 years, has discovered the science to explain the “why” in this terrible disease: “why does the brain lose synapses and develop amyloid plaques?” Once the “why” is known, the treatment can be optimized.

There is no single treatment, drug, or supplement that one can take to reverse Alzheimer’s. However, by optimizing the 36-50 known factors that lead to the neurodegeneration of the disease, cognition can be restored.

Because there are so many variables, the treatment must be individualized for each patient. Every patient’s treatment will be different. Like anything in functional medicine, we must find the root cause of the problem, and correct the abnormalities. The earlier the symptoms are discovered, the better the likelihood of returning to normal cognition.

WWMT Channel 3 Live Interview

Cognoscopy

Everyone knows that a colonoscopy is recommended at age 50 to reduce the chance of getting colon cancer.

Since there was no treatment, many would not want to know if they were at risk of getting Alzheimer’s disease. However, we now know, that identifying those at risk, looking for underlying metabolic abnormalities, and correcting them, can prevent the cognitive decline that previously was their fate.

A cognoscopy is an evaluation to look for these risk factors and abnormalities. This is recommended at age 45.

This evaluation requires multiple appointments. The initial appointment is 2-3 hours in length. This involves time with a provider as well a nutrition counselor and nurse. After the appropriate testing is determined, there is a 2 hour follow up an appointment to review the results and formulate a treatment plan.

Lectures

Dr. Koziarski gives frequent educational talks on this topic. They are free and open to the public. Look for the next talk date coming soon!
Dr. Koziarski and the Restorative Health Care team are passionately committed to ending the ravishing effects of Alzheimer’s Disease.

  1. Bredesen DE. Reversal of cognitive decline: A novel therapeutic program. Aging (Albany NY). 2014; 6:707-717. https://doi.org/10.18632/aging.100690

No products were found matching your selection.